|
|
Neurogen Corporation - Comparative Business Analysis Snapshot
Business Description
Neurogen Corporation. The Group's principal activities are to discover and develop new drugs for the treatment of neurological, inflammatory, pain and metabolic disorders. Through its Accelerated Intelligent Drug Discovery (TM) platform, it discovers compounds that hit new potential drug targets, evaluates the utility of those targets and optimizes useful leads into new drug candidates. The Group has collaboration agreements with Aventis Pharmaceuticals for the discovery and research of CRF1 receptor-based drugs and collaboration agreement with Merck Sharp & Dohme Limited to research, develop, and commercialize small molecule medicines. It also has a technology transfer agreement with Pfizer Inc. for the licensing and transfer of the Group's proprietary technologies for the discovery of new drugs to Pfizer as well as collaboration agreements for the discovery of GABA-based drugs for anxiety and cognitive disorders.
Competitor Analysis
This analysis compares Neurogen Corporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
